POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

Rhea-AI Summary

POMDOCTOR LIMITED (NASDAQ: POM) announced it has formally initiated preparations for entering the U.S. healthcare market, positioning this step as a key element of its global expansion strategy. The company has started recruiting U.S.-based leadership and operational staff, completed an initial assessment of the U.S. healthcare landscape, and begun building a local compliance and regulatory framework.

According to Pomdoctor, it is also localizing its AI-enabled healthcare products and holding exploratory discussions with potential U.S. partners. The U.S. expansion is planned as a multi-phase process, starting with pilot validation in areas such as remote patient monitoring and chronic disease management, followed by deeper engagement with payers, providers and ecosystem participants, and eventual regional commercial deployment.

Positive

• Formal start of U.S. market preparations with hiring and regulatory groundwork
• Planned multi-phase U.S. rollout beginning with pilots in RPM and chronic disease management
• Leverages existing Chinese platform including proprietary AI, wearables and real-world data infrastructure

Negative

• None.

News Market Reaction – POM

+0.01% 22.5x vol

4 alerts

+0.01% Session close to close

+5.0% Peak Tracked

$7.83M Market Cap

22.5x Rel. Volume

In the Aug 27 session, POM gained 0.01%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 22.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy.

As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework. Concurrently, the Company is advancing product localization efforts and engaging in exploratory discussions with potential U.S. partners across the healthcare sector.

Pomdoctor U.S. expansion will follow a disciplined, multi-phase approach. The initial stage centers on pilot validation, including potential applications in remote patient monitoring ("RPM") and chronic disease management. Upon successful pilot outcomes, the Company intends to deepen engagement with healthcare payers, healthcare providers and other ecosystem players, before progressively scaling toward broader commercial deployment across selected regional markets.

The U.S. initiative builds on Pomdoctor's proven proprietary healthcare platform, extensive physician network, proprietary AI algorithms, wearable technologies and solid real-world data ("RWD") infrastructure, all of which have been clinically validated and iteratively enhanced in the Chinese market. The Company believes these core competencies and the tested operating model are replicated and scalable in the U.S. and other international markets.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented, "Our U.S. market preparation represents a pivotal milestone in translating our global strategy into execution. We are committed to a disciplined, measurable phase-driven entry, prioritizing local validation and ecosystem development before pursuing broader commercialization. Over the long term, we believe our U.S. operations will serve as a foundational pillar of our global predictive healthcare platform, establishing a replicable template for our expansion into additional high-value markets worldwide."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-initiates-us-market-preparation-and-unveils-expansion-strategy-302861633.html

SOURCE POMDOCTOR LIMITED

FAQ

What did POMDOCTOR LIMITED (NASDAQ: POM) announce about its U.S. market plans on August 27, 2026?

POMDOCTOR LIMITED announced it has formally begun preparing for a U.S. market entry. According to Pomdoctor, this includes leadership hiring, market assessment, regulatory framework development, product localization and early partner discussions as part of a structured global expansion strategy.

How will POMDOCTOR LIMITED structure its U.S. expansion strategy for POM stock investors?

Pomdoctor plans a disciplined, multi-phase U.S. expansion starting with pilot validation projects. According to Pomdoctor, successful pilots would be followed by deeper engagement with payers and providers, then gradual commercial deployment across selected U.S. regional markets.

Which healthcare areas will POMDOCTOR LIMITED target first in its U.S. market entry?

Pomdoctor initially targets pilot validation in remote patient monitoring and chronic disease management. According to Pomdoctor, these pilots are intended to locally validate its AI-enabled healthcare platform before expanding to broader U.S. commercial deployment.

How does POMDOCTOR LIMITED plan to use its Chinese healthcare platform in the U.S. market?

Pomdoctor intends to build on its existing platform, physician network, AI algorithms, wearables and real-world data infrastructure. According to Pomdoctor, these capabilities have been clinically validated in China and are viewed as scalable to the U.S. and other markets.

What role does the U.S. business play in POMDOCTOR LIMITED’s global strategy for POM shareholders?

Pomdoctor views U.S. operations as a future foundational pillar of its global predictive healthcare platform. According to Pomdoctor, the U.S. model is expected to provide a template for expansion into additional high-value international markets.

Is POMDOCTOR LIMITED already partnering with U.S. healthcare organizations as part of its expansion?

Pomdoctor is currently engaging in exploratory discussions with potential U.S. partners across the healthcare sector. According to Pomdoctor, these talks support early-stage market preparation ahead of broader commercialization and deeper ecosystem engagement.